The abilityof R.E to induce a robust IFN-β response from tumor cells highlightsa new mechanism of action that, when combined with advanced drug deliverysystems, may pave the way for more effective and less toxic immunotherapeuticregimens. Here, IFNB1 is linked to neoplasm.